HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 04, April 2019 – Career development for researchers       » CRISPR not as precise as thought       » Insomnia spreads among young Chinese       » Chinese HEV vaccine begin clinical trial in U.S       » Eating mushrooms may reduce risk of cognitive decline       » Green tea cuts obesity in mice      
INSIDE INDUSTRY
Forxiga approved in Japan for type-1 diabetes
It is also the first AstraZeneca medicine ever approved for type-1 diabetes

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T1D).

Elisabeth Björk, senior vice president, head of late cardiovascular, renal and metabolism, R&D BioPharmaceuticals, AstraZeneca said, “This approval of Forxiga in Japan means that people with type-1 diabetes whose glucose levels are not adequately controlled with insulin alone now have a new oral treatment option available to them.”

The approval is based on data from the Phase III DEPICT clinical programme and a dedicated trial in Japanese patients.

Forxiga was approved by the European Commission on 20 March as the first oral adjunct treatment in Europe for adults with T1D. The medicine is under regulatory review in the US for the same indication, with a decision expected in the second half of 2019.

Forxiga is the first AstraZeneca medicine ever approved for type-1 diabetes.

Click here for the complete issue.

NEWS CRUNCH  
news Which country has the worst sleepers
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy